Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
|
|
- Elinor Stanley
- 6 years ago
- Views:
Transcription
1 LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC Each year more patients present with prostate cancer at increasingly younger ages and with earlier stage disease, resulting in the potential for longer survival time, longer-term hormonal therapy, and a heightened risk of developing biochemical recurrence after treatment. It seems clear that clinicians need to broaden the definition of advanced prostate cancer to include recent knowledge that will influence the form and timing of treatment as well as the monitoring of disease progression. A more contemporary definition should include patients with lower-grade disease and with an increased risk of progression and/or death from prostate cancer along with those with widely disseminated metastatic disease. Treatment alternatives for these patients should be evaluated based on a risk stratification equation toward a goal of the greatest efficacy and the least patient harm over time given that increasing numbers of these patients are entering treatment long before they develop widespread osteoblastic metastases. [Rev Urol. 24;6(suppl 8):S1-S17] 24 MedReviews, LLC Key words: Advanced prostate cancer Risk stratification Prostate-specific antigen Early hormonal therapy Metastasis Recurrence Biochemical recurrence Hormones Prostate cancer, second only to skin cancer incidence among men in the United States, will affect an estimated 23,1 men during It is further estimated that 1 in 6 US men will develop prostate cancer during his lifetime and that over 7% of these cases will be among men older than age 65. 1,2 Incidence rates reached a peak in the mid 199s, following widespread use of prostate-specific antigen (PSA) screening programs; these rates subsequently declined and currently are increasing, albeit at a less rapid pace. 1,3 Prostate cancer S1 VOL. 6 SUPPL REVIEWS IN UROLOGY
2 Advanced Prostate Cancer: Evolving Definition remains the second leading cause of cancer deaths among US men, accounting for close to 3, deaths annually, a total that is exceeded only by the number of deaths from lung cancer. 1 Age of diagnosis continues to decrease with a concomitant increase in the number of men diagnosed with earlystage or clinically localized disease. 1,4 In addition, over the past 1 years the age-adjusted death rate has decreased approximately 15%, partly due to earlier detection and in part to improved treatment of both early stage and advanced disease. 1,4-6 As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with rising PSA levels. Such PSA relapses, conservatively estimated to affect around 5, men each year, have become the most common form of advanced prostate cancer in the current PSA era. 1,7-9 Contemporary Prostate Cancer Traditionally, advanced prostate cancer was defined as disease that had widely metastasized beyond the prostate, the surrounding tissue, and the pelvic lymph nodes, and was considered incurable by most clinicians and patients The average patient had symptomatic stage D-2 disease and the most common symptom was bone pain that caused physicians to seek therapy for this form of the disease. 11,12 However, given the changing face of the disease (ie, younger, healthier, better informed men with lower-grade disease), and the fact that the pathogenicity of the cancer and the risk of its metastasis were not considered, it seems clear that we need to rethink the definition of advanced prostate cancer The current evidence suggests that patients with significant risk of progressive disease and/or death from prostate cancer should be included in the definition and that any patient with cancer outside the prostate capsule with disease stages as low as T3/N/M clearly has advanced disease and should be treated accordingly. 12,13 Evolving Definition of Advanced Prostate Cancer Currently, younger and healthier men are being diagnosed with prostate cancer and treated with a variety of modalities (eg, hormonal therapy, brachytherapy, and external beam radiotherapy) for locally advanced disease, as well as older men with rising PSA levels years after being treated with a radical prostatectomy. Both scenarios define current advanced disease and underscore the necessity of modifying the disease definition and treatment plans to reflect this broader spectrum of patients and disease states. The definition now must be broadened to reflect younger, healthier men with a significant risk of disease progression, the potential for longer survival, and possibly prolonged treatment with hormone therapy. With the acceptance and proliferation of PSA screening, there has clearly been a stage migration in disease; many otherwise healthy patients now present with local lymph node metastasis or stage T3 disease that progresses to distant metastasis. 14 Most of these patients A contemporary definition of advanced prostate cancer should consider including stages C and D1. Rate of Bone Metastasis at Diagnosis (%) do not have any significant comorbidities and very few have bone metastasis at diagnosis (Figure 1). Analysis of the Department of Defense Center for Prostate Disease Research (CPDR) database demonstrates this migration with decreasing proportions of patients presenting with bone metastasis at the time Diagnosis Year (N=1,686) Figure 1. Stage migration: Decreasing rate of patients presenting with clinical metastasis (stage D1/D2) at diagnosis. Data from Department of Defense Center for Prostate Disease Research. VOL. 6 SUPPL REVIEWS IN UROLOGY S11
3 Advanced Prostate Cancer: Evolving Definition continued Constituent Age Ratio (%) >7 65~7 6~65 55~6 <55 of diagnosis (Figure 1). In 199, almost 12% of these men were diagnosed with advanced disease (D1/ D2); 12 years later, less than 5% of the newly diagnosed patients had metastatic prostate cancer. Thus, a contemporary definition of advanced prostate cancer should consider including stages C and D1. 4,12 In addition to the stage migration, CPDR data also documented a clear age migration of the disease (Figure 2). 15 In the early 199s, prostate cancer Diagnosis Year Figure 2 Age migration: Decreasing age of patients diagnosed with prostate cancer. Data from Department of Defense Center for Prostate Disease Research. was mainly a diagnosis of men over age 7. Over the years, as we have moved through the PSA era (1991- present), the proportion of men diagnosed under age 55 more than doubled to almost 15% of all cases. 4 Thus, we are seeing younger and younger patients being diagnosed with localized prostate cancer, all with the potential of long-term survival as well as long-term hormonal therapy. Evolving Treatment for Advanced Prostate Cancer Concomitant with the changing definition of advanced prostate cancer is the continuing evolution of treatment regimens for the disease. Now, more than ever, it is important to balance the risk of treatment with the benefits derived because of the likelihood of longer survival and the We are seeing younger and younger patients being diagnosed with localized advanced prostate cancer, all with the potential of long-term survival as well as long-term hormonal therapy. probability of disease progression with increasing symptoms, resulting in a decreased quality of life over an extended period of time. In addition, there is growing acknowledgment that prognostic markers such as age, PSA levels, Gleason scores, and tumor stage can help identify those patients most likely to experience disease progression and death from prostate cancer. 13,15-19 The use of such a risk stratification system, particularly for younger patients, permits modification of the timing and form of the treatment prescribed. Currently, treatment for advanced prostate cancer is being modified to include: Neoadjuvant/adjuvant hormonal therapy Earlier use of hormonal therapy Risk-stratified early Rx in PSArecurrent disease Traditional versus nontraditional hormonal therapy Luteinizing hormone-releasing hormone agonists (the mainstay of treatment for some 5 years) Antiandrogen monotherapy Intermittent hormonal therapy (appealing because it minimizes potentially deleterious effects of long-term hormonal treatment) Clearly many contemporary men are better informed about health in general and their disease in particular and thus, there is much less blanket acceptance of traditional hormonal therapy with its accompanying side effects that could last for many years. Many of these men are concerned about such therapy and are looking to us for alternatives, particularly given the possibility of longterm treatment. Risk Stratification As indicated previously, stratifying the risk of disease progression is important in determining the timing and treatment regimens for patients with locally advanced prostate cancer. 13,2 In a recently published article, D Amico and colleagues 13 presented PSA-era validation of a risk stratification nomogram for clinically localized prostate cancer. Patients categorized as having high risk localized disease (Table 1) have PSA S12 VOL. 6 SUPPL REVIEWS IN UROLOGY
4 Advanced Prostate Cancer: Evolving Definition Low Risk Table 1 Risk Stratification in Clinically Localized Disease Intermediate Risk High Risk PSA < 1 ng/ml and Gleason biopsy 6 and 1992 AJCC T1 c,2 a PSA 1 2 ng/ml or Gleason biopsy 7 or 1992 AJCC T2 b PSA > 2 ng/ml or Gleason biopsy 8 or 1992 AJCC T2 c the men who were treated with external beam radiation, mortality from prostate cancer was quite high among those in the high-risk category (Figure 4). These data demonstrate that there is obvious room for improvement in multimodality therapy, underscoring the premise that high risk patients, receiving either surgery or radiotherapy, could be considered to have contemporarily advanced disease. PSA, prostate-specific antigen; AJCC, American Joint Committee on Cancer; T, tumor. Adapted from D Amico AV et al. 13 levels above 2 ng/ml or a Gleason score 8, or the 1992 American Joint Committee on Cancer tumor stage T2 c or T3. These patients, particularly the younger men, could now be defined as advanced prostate cancer patients because of their increased risk for death from the disease, even though it is detected at a localized stage. The study included data from 2 multi-institutional databases of more than 6 patients treated with either radical prostatectomy or radiation therapy. The data were combined and stratified according to pretreatment risk (low, intermediate, and high) and age at initial therapy. As shown in Figure 3, surgery is effective during the first 1 years, but prostate cancer-specific mortality remains significant, particularly for the men at high risk. Similarly for Biochemical Recurrence Rising PSA levels after initial/radical therapy is frustrating and disappointing for both urologists and patients, particularly the younger patients who are generally relatively healthy otherwise. Since approximately 4% of men who originally receive localized treatment will Surgery is effective during the first 1 years, but prostate cancer-specific mortality remains significant for high risk younger men. eventually experience PSA-only recurrence, PSA relapse has become the most common form of advanced 1 Age (Years) When Treated <6 <6 64 < Age (Years) When Treated <6 <6 64 < Percent of Patients Alive Low Risk Intermediate Risk Percent of Patients Alive Low Risk Intermediate Risk High Risk Years Following Surgery High Risk Years Following Surgery Figure 3. Mortality (prostate cancer- and non-prostate cancer-specific) after radical prostatectomy stratified by age at time of initial therapy and pretreatment risk group. Blue, prostate cancer-specific mortality; red, non-prostate cancer-specific mortality. Reproduced with permission from D Amico AV et al. 13 Figure 4. Mortality (prostate cancer- and non-prostate cancer-specific) after radiation therapy stratified by age at time of initial therapy and the pretreatment risk group. Blue, prostate cancer-specific mortality; red, non-prostate cancer-specific mortality. Reproduced with permission from D Amico AV et al. 13 VOL. 6 SUPPL REVIEWS IN UROLOGY S13
5 Advanced Prostate Cancer: Evolving Definition continued prostate cancer in the current PSA era. 4,7,9 Rising PSA levels usually represent the earliest sign of advanced disease and/or an indication of residual tumor with an implicit negative impact on the patient s natural life span and his quality of life. 21,22 Both the urologist and the patient face challenging treatment decisions. 7 Early Hormone Therapy One of the dilemmas faced by clinicians treating a young patient with PSA relapse is whether to initiate hormone therapy early in the course of the secondary treatment. Arguments favoring early hormonal therapy include the fact that the clinical situation is fairly easy to define and monitor, and the increasing evidence demonstrates clear survival advantages associated with early hormone therapy for high risk malignancies. 23,24 In addition, as Dr. Brawer points out in this supplement, 25 in both the adjuvant and neoadjuvant setting, early hormonal therapy may increase the cure rates of conventional therapies. Another powerful argument for initiating hormone treatment early in biochemical recurrence is that watchful waiting is no longer an acceptable option for most men. Many contemporary men and their families are increasingly better informed than their counterparts a decade or so ago. Thus, many men faced with rising PSA levels consider metastatic disease to be an inevitable consequence of treatment delay and understandably are concerned. Arguments for early hormonal therapy are countered, however, by a number of factors, including: The long natural history for most men of rising PSA levels before clinical metastases and death No randomized controlled clinical trials to confirm the survival advantage or to document the long-term effects of such therapy Clinical Metastasis free Survival (%) P = The side effects of hormone therapy, particularly for younger men Costs of hormone treatment, particularly if over a long period of time The classic study by Pound and associates 26 reported an average of 8 years between PSA relapse after a radical prostatectomy and clinical manifestation of metastatic disease. Once hormone therapy was initiated, the patients lived, on average, for another 5 years. In total, there was an average of 13 years separating biochemical recurrence and death for these surgically treated men: a relatively long period of time for the older patients, but not very reassuring or acceptable for the younger patients. Once again, the key is to take a risk-stratified approach to Early HT Late HT Time (Years) Time zero is from PSAR (PSA after surgery >.2 ng/ml) Figure 5. Early hormonal therapy (HT) administered at PSA 5 ng/ml or less affects clinical metastasis survival in patients with pathological Gleason sum greater than 7 or PSA-DT 12 months or less. Time zero is from PSAR time. PSA, prostate-specific antigen; PSA-DT, PSA doubling time; PSAR, PSA relapse only. Reproduced with permission from Moul JW et al. 9 biochemical recurrence when determining the appropriate therapy to be recommended and pursued. Early Versus Delayed Therapy In our recently published article in the Journal of Urology, 9 we reported results of early versus delayed hormonal treatment for PSA-only recurring prostate cancer after a radical prostatectomy among 1352 patients in the CPDR database. Differences in outcome and time to the development of clinical metastasis were In both the adjuvant and neoadjuvant setting, early hormonal therapy may increase the cure rates of conventional therapies. measured, stratified by risk status (high risk PSA recurrence versus lower risk PSA relapse) and time of hormone therapy initiation (ie, early [after PSA only relapse but before clinical metastasis] or late [therapy at time of clinical metastasis or none received by follow-up]). The median S14 VOL. 6 SUPPL REVIEWS IN UROLOGY
6 Advanced Prostate Cancer: Evolving Definition Bone Metastasis free Survival (%) P = Early HT Late HT Time (Years) Time zero is from PSAR (PSA after surgery >.2 ng/ml) Figure 6. Early hormonal therapy (HT) administered at PSA 1 ng/ml affects clinical metastasis-free survival in patients with pathological Gleason sum greater than 7 or PSA-DT 12 months or less. Time zero is from PSAR time. PSA, prostate-specific antigen; PSA-DT, PSA doubling time; PSAR, PSA relapse only. Reproduced with permission from Moul JW et al. 9 Bone Metastasis free Survival (%) P =.4 Late HT Early HT Time (Years) Time zero is from PSAR (PSA after surgery >.2 ng/ml) Figure 7. Early hormonal therapy (HT) administered at PSA 5 ng/ml or less did not affect clinical metastasisfree survival in the overall cohort of 1,352 patients with PSAR at current followup. Time zero is from PSAR time. PSA, prostate-specific antigen; PSAR, PSA relapse only. Reproduced with permission from Moul JW et al. 9 follow-up period was 5.5 years after PSA relapse. We found a benefit for early hormonal therapy when it was administered at PSA 5 ng/ml versus those who started therapy with a PSA > 5 ng/ml (Figure 5). However, this benefit was limited to patients who had high risk PSA relapse. The high risk PSA-only recurrence was defined as those patients who developed a rising PSA doubling time that was 1 year or had a Gleason score of 8, 9, or 1 in their radical prostatectomy specimen. Results indicated that the high risk individuals with biochemical recurrence who received early hormonal therapy experienced a delayed time to the development of bony metastasis. Thus, the natural history of bone metastasis in this group of men was changed. And similarly, high risk men who received early hormone therapy with PSA levels 1 ng/ml also experienced delayed clinical metastasis (Figure 6). However, when data for the entire cohort were analyzed, there was no such delay in the development of clinical metastasis with early hormonal therapy (Figure 7). The reason for this apparent discrepancy is that risk of progression was not taken into account in this analysis. The total sample included all men with a biochemical recurrence (PSA >.2 ng/ml), regardless of risk stratification. Nonetheless, this study was the first to demonstrate a clinical disease-free survival benefit for early hormonal therapy and PSA-only relapse. It also emphasizes the critical importance of risk stratification as we demonstrated a benefit for high risk individuals, patients with rapid PSA doubling time, and patients with high-grade disease. For such patients, it seems reasonable to use early hormonal therapy. It must be cautioned, however, that these data are from a database, not a randomized clinical trial, and thus the outcomes may change with additional years of follow-up and as more patients are treated with hormone therapy for PSA relapsing disease. In addition, an overall survival benefit could not be determined given the relatively short follow-up VOL. 6 SUPPL REVIEWS IN UROLOGY S15
7 Advanced Prostate Cancer: Evolving Definition continued period (5.5 years), although we were able to demonstrate delayed bone metastasis among high risk patients. Doubling time. With regard to PSA recurrence, PSA doubling time is critically important. 27,28 As previously indicated, a doubling time of less than 1 year clearly identified high risk individuals individuals who had delayed bone metastasis when hormone therapy was started early. With D Amico and colleagues 28 we studied PSA doubling time < 3 months and found a direct correlation between this short doubling time and death from prostate cancer. Thus it seems clear that PSA doubling time is a very important prognostic factor in biochemical recurrence and that early hormone therapy should be considered in efforts to delay metastatic disease when the doubling time is less than 3 to 12 months. Conclusion Since the introduction and widespread use of PSA testing in the late 198s, the face of advanced prostate cancer has been changing, and this change is profound. Years ago, advanced prostate cancer patients typically were men with bone metastasis. Nowadays, we are increasingly This study was the first to demonstrate a clinical disease-free survival benefit for early hormonal therapy in the settng of PSA-only relapse. seeing younger patients, patients with biochemical recurrence, and patients with locally advanced prostate cancer. These men all have potentially advanced prostate cancer with its attendant poor prognosis. Currently, high risk localized disease and PSA recurrence are the most common presentations of advanced prostate cancer. Although PSA relapse is becoming so much more common, there are still no randomized controlled clinical trials to help us make informed clinical decisions based on more contemporary data. Observational data, however, seem to indicate that high-risk individuals (ie, those with high-grade disease and with PSA doubling time less than 12 months) benefit from early hormone therapy. The long-term consequences of such therapy, however, are unknown and may be potentially deleterious. 29,3 The final question concerning the efficacy of early versus late hormone therapy for PSA relapse remains unanswered because of the need for longer follow-up in order to assess overall and improved survival for Although PSA relapse is becoming so much more common, there are still no randomized controlled clinical trials to help us make informed clinical decisions based on more contemporary data. men with advanced prostate cancer. We await with great anticipation results from additional research and directed clinical trials. References 1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 24. CA Cancer J Clin. 24;54: Wilt TJ. Prostate cancer: epidemiology and screening. Rev Urol. 23;5(suppl 6):S3-S9. 3. Stephenson RA. Population-based prostate cancer trends in the PSA era: data from the Main Points There is a profound change in the face of advanced prostate cancer. High-risk localized and prostate-specific antigen (PSA) recurrence are the most common forms of advanced prostate cancer. More men diagnosed with advanced prostate cancer enter treatment long before they develop distant metastases. Because many patients with T3 disease or local lymph node metastases progress to distant metastases, the concept of advanced prostate cancer should also include stages C and D1 (T3, T4, and any T N1). Many men treated for clinically localized disease will progress rapidly and, depending on their age, general health, and selected prognostic markers, should be included in the advanced-disease category. There are no randomized controlled clinical trials to guide clinicians in treatment decisions for men with PSA recurrent disease. Current observational studies, however, indicate the utility of taking a risk stratified approach to PSA relapse patients and the form and content of their treatment. Men with high grade disease (Gleason score above 7) and those with short PSA doubling time (under 12 months) have delayed clinical metastasis if they receive early hormonal therapy. It is unknown if early hormonal therapy for PSA recurrent disease will improve prostate cancer-specific or overall survival. S16 VOL. 6 SUPPL REVIEWS IN UROLOGY
8 Advanced Prostate Cancer: Evolving Definition Surveillance, Epidemiology, and End Results (SEER) Program. Monogr Urol. 1998;19: Moul JW, Wu H, Sun L, et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 22;132: Catalona WJ, Smith DS, Radiff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigenbased screening. JAMA. 1993;27: Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence in advanced stage disease, 1974 to J Urol. 1997;158: Moul JW. Prostate specific antigen only progression of prostate cancer. J. Urol. 2;163: Djavan B, Moul JW, Zlotta A, et al. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol. 23;21: Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 24;171: Crawford ED. Changing concepts in the management of advanced prostate cancer. Urology. 1994;44: Moul JW. A better definition of advanced prostate cancer for today s patients. Contemp Urol. 1997;9: Moul JW. Treatment of metastatic prostate cancer. Braz J Urol. 2;26: D Amico AV, Moul J, Sun L, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 23;21: Epstein BE, Hanks GE. Prostate cancer: evaluation and radiotherapeutic management. CA Cancer J Clin 1992;42: Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995; 45: Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;9: Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17: D Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology. 21;15: Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 21; 166: D Amico AV, Cote K, Loffredo M, et al. Determinants of prostate-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 22; 2: Yu H, Diamandis EP, Presigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem. 1995;41: Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate specific antigen after anatomical radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24: Kirk D. Immediate vs. delayed hormone treatment for prostate cancer: how safe is androgen deprivation? Brit J Uro Int. 2;86(suppl):22. Abstract MP Messing EM, Monola J, Sarodsy M, et al. Immediate hormonal therapy compared with observation following radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341: Brawer MK. Androgen deprivation therapy. A cornerstone in the treatment of advanced prostate cancer. Rev Urol. 24;6(suppl 8):S3- S Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281: D Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 24;351: D Amico AV, Moul JW, Carroll PR, et al. Surrogate end points for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 23;95: Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157: Preston DM, Torrens JI, Duncan WE, McLeod DG. Evaluation of bone mineral density in men receiving total androgen blockage therapy for prostate cancer: preliminary results. J Urol. 1977;157(suppl):335. Abstract 131. VOL. 6 SUPPL REVIEWS IN UROLOGY S17
CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationEARLY VERSUS DELAYED HORMONAL THERAPY FOR PROSTATE SPECIFIC ANTIGEN ONLY RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
0022-5347/04/1713-1141/0 Reprinted from Vol. 171, 1141 1147, March 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000113794.34810.d0
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationUCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Permalink https://escholarship.org/uc/item/24j7405c
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationincision into an otherwise organ-confined cancer [1,5].
28 The Authors. Journal compilation 28 BJU International Original Article IMPACT ON PROGRESSION OF POSITIVE SURGICAL MARGINS AFTER RP PFITZENMAIER et al. BJUI BJU INTERNATIONAL Positive surgical margins
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationPROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive
Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationNomograms for prostate cancer
Review Article NOMOGRAMS FOR PROSTATE CANCER STEPHENSON and KATTAN There are several papers in this section on various aspects of prostate cancer: predictive models, robotic radical prostatectomy in large
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationPROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationInvasion of the muscular wall of the seminal vesicles by prostate cancer is generally
PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationThe Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
european urology 51 (2007) 940 948 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Natural History of Noncastrate Metastatic Prostate Cancer after Radical
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationMoul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:
See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/12518552 Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-1642
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationInt. J. Cancer: 120, (2006)
Int. J. Cancer: 120, 170 174 (2006) ' 2006 Wiley-Liss, Inc. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationGood Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic Prostatectomy
european urology 54 (2008) 344 352 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Good Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationRadical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens
ORIGINAL ARTICLE Detection of Positive Margins and Extraprostatic Extension Viacheslav Iremashvili, MD, PhD,* Soum D. Lokeshwar,* Mark S. Soloway, MD,* Lise tpelaez,md,w Saleem A. Umar, MD,w Murugesan
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationThe Selenium and Vitamin E Prevention Trial
The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More informationTHE MOST COMMON definitive therapy for the treatment
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Michael W. Kattan, Thomas M. Wheeler, and Peter T. Scardino Purpose: Although models exist that place patients
More informationRADICAL PROSTATECTOMY IS SElected
ORIGINAL CONTRIBUTION Adjuvant for Pathologically Advanced Prostate Cancer A Randomized Clinical Trial Ian M. Thompson, Jr, MD Catherine M. Tangen, DrPH Jorge Paradelo, MD M. Scott Lucia, MD Gary Miller,
More information